Compare SE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SE | ARGX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Singapore | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9B | 58.4B |
| IPO Year | 2017 | 2017 |
| Metric | SE | ARGX |
|---|---|---|
| Price | $95.19 | $939.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 29 | 10 |
| Target Price | $156.65 | ★ $1,180.17 |
| AVG Volume (30 Days) | ★ 2.5M | 203.7K |
| Earning Date | 11-10-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.78 | $47.90 |
| Revenue Next Year | $22.80 | $21.64 |
| P/E Ratio | $49.15 | ★ $33.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $77.05 | $661.85 |
| 52 Week High | $193.48 | $1,072.75 |
| Indicator | SE | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 47.73 |
| Support Level | $81.51 | $836.30 |
| Resistance Level | $98.89 | $1,072.75 |
| Average True Range (ATR) | 2.95 | 18.68 |
| MACD | -0.69 | -5.14 |
| Stochastic Oscillator | 0.95 | 45.67 |
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.